SUPPLEMENTARY INFORMATION

Nanoengineering the surface of corneal implants: Towards functional anti-microbial and biofilm materials

Zohra Khatoon,[a] Irene Guzman,[a] Christopher McTiernan,[a] Caitlin Lazurko,[a] Fiona Simpson,[b] Li Zhang,[c] David Cortes,[a] Thien-Fah Mah,[c] May Griffith,[b,d*] Emilio I. Alarcon[a,c*]

[a]Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Canada.[b]Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada. [c]Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada. [d]Département d'ophtalmologie, Université de Montréal, Montréal, QC, Canada. E-mail: may.griffith@umontreal.ca & ealarcon@ottawaheart.ca

Table of contents

Page S1. This page

Page S2. Figure S1. Changes in the surface plasmon band absorption as a function of the irradiation time for nanoparticles prepared at different peptide concentrations.

Page S3. Figure S2. Young modulus for corneal implants before and after nanosilver-peptide grafting.

Page S4. Figure S3. Expression of CD40, CD80, or CD86 relative to untreated BMDCs for the different experimental groups.

Page S5. Figure S4. Relative to control cytokine levels measured by multiplex sample analysis.

Page S6. Figure S5. A representative example of the gating strategy used in the dendritic cell experiments.

Page S7. Table S1. Summary for dendritic cell flow-cytometry antibody protocol dilution.



Figure S1. Changes in the surface plasmon band (SPB) absorption as a function of the irradiation time for nanoparticles prepared at different peptide concentrations prepared onto the corneal implants. Samples were measured at their respective SPB maximun. Error bars correspond to standard deviation from the mean (n=4), measured at room temperature.



Figure S2. Young modulus for corneal implants before and after nanosilver-peptide grafting. Error bars correspond to standard deviation from the mean (n=5-7), measured at room temperature.



Figure S3. Expression of CD40, CD80, or CD86 relative to untreated BMDCs for the different experimental groups. Cells were precultured on the corneal implants with and without the peptide-nanosilver prepared at different peptide concentration.



Figure S4. Relative to control cytokine levels measured by multiplex sample analysis (n=3). Samples were measured after 72h post-subcutanous implantation (see experimental). In all cases, but for MMP12 (20 vs 100 μM CLKRS) there were no significant differences.



Figure S5. A representative example of the gating strategy used in the dendritic cell experiments.

Table S1. Antibodies for BMDC Flow Cytometry (see main text experimental for further details).

Target	Antibody	Dilution Factor
CD11c	Brilliant Violet 650™ anti-mouse CD11c,(Clone: N418),(IsoType: Armenian Hamster IgG),(Reactivity: Mouse),(Format: BV650),(APP: FC),(Species: Hamster), Biolegend, 117339	1/1600
IA-IE (MHC Class II)	PerCP/Cy5.5 anti-mouse I-A/I-E,(Clone: M5/114.15.2),(IsoType: Rat IgG2b, κ),(Reactivity: Mouse),(Format: PerCP/Cy5.5),(APP: FC),(Species: Rat), Biolegend, 107626	1/3200
CD40	CD40, APC, clone: 1C10, eBioscience™, 501129392	1/400
CD80	PE anti-mouse CD80,(Clone: 16-10A1),(IsoType: Armenian Hamster IgG),(Reactivity: Mouse, Cross-Reactivity: Dog (Canine)),(Format: PE),(APP: FC),(Species: Hamster), Biolegend, 104708	1/100
CD86	FITC anti-mouse CD86,(Clone: GL-1),(IsoType: Rat IgG2a, κ),(Reactivity: Mouse),(Format: FITC),(APP: FC),(Species: Rat), Biolegend, 105006	1/50